US stock · Healthcare sector · Biotechnology
B
Bio-Techne Corporation
TECH
NASDAQ78.43
USD
-0.86
(-1.08%)
Market Closed
46.04P/E
33Forward P/E
2.18P/E to S&P500
12.348BMarket CAP
0.40%Div Yield
Upcoming Earnings
2 Aug-7 Aug
Shares Short
5/31/23
3.04M
Short % of Float
2.50%
Short % of Shares Outs.
1.93%
% Held by Insiders
0.89%
% Held by Institutions
96.51%
Beta
1.24
PEG Ratio
3.76
52w. high/low
99.33/68.00
Avg. Daily Volume
1.01M
Return %
Stock
S&P 500
1 year
(28.45)
(9.05)
3 years
67.65
50.26
5 years
96.07
38.50
Scale: |
High
Low
20.73
14.28
17.49
11.35
17.43
13.91
21.61
15.51
19.00
15.77
23.70
15.64
24.29
20.63
28.64
20.97
29.36
19.99
34.10
23.92
51.51
32.02
55.82
33.65
81.61
38.79
135.96
77.66
129.76
68.00
88.84
69.81
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
1.42
1.64
1.75
1.81
1.95
2.13
2.11
2.42
3.05
3.35
3.77
4.29
4.72
4.83
6.01
7.05
7.13
Earnings per share
0.54
0.66
0.70
0.74
0.76
0.76
0.76
0.75
0.73
0.70
0.51
0.84
0.64
1.50
0.91
1.73
1.62
FCF per share
0.52
0.63
0.69
0.72
0.83
0.82
0.69
0.83
0.81
0.85
0.86
1.00
1.03
1.00
1.99
1.79
1.61
Dividends per share
- -
- -
0.19
0.26
0.27
0.28
0.29
0.31
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
0.32
CAPEX per share
0.05
0.10
0.04
0.03
0.02
0.04
0.15
0.09
0.13
0.11
0.10
0.14
0.17
0.34
0.29
0.29
0.28
Book Value per sh.
2.78
3.11
3.02
3.37
3.95
4.56
5.01
5.39
5.71
5.91
6.36
7.20
7.71
9.04
10.08
10.85
11.14
Comm.Shares outs.
158
157
151
149
148
148
147
148
148
149
149
150
151
153
155
157
157
Avg. annual P/E ratio
28.0
26.7
21.8
21.1
24.0
22.8
24.4
30.2
33.0
36.0
56.2
47.1
77.5
40.8
121.3
52.6
46.0
P/E to S&P500
1.6
1.2
0.3
1.0
1.5
1.5
1.4
1.7
1.7
1.6
2.4
1.9
3.2
1.1
4.0
2.5
2.2
Avg. annual div. yield
- -
- -
1.2%
1.7%
1.5%
1.6%
1.6%
1.4%
1.3%
1.3%
1.1%
0.8%
0.6%
0.5%
0.3%
0.4%
0.4%
Revenue (m)
223
257
264
269
290
315
311
358
452
499
563
643
714
739
931
1,106
1,120
Operating margin
55.6%
56.1%
57.1%
58.1%
56.2%
52.8%
51.0%
44.7%
32.5%
30.2%
21.4%
21.2%
20.5%
21.3%
25.5%
26.8%
26.2%
Depreciation (m)
7
7
8
8
9
12
12
19
37
43
60
64
78
83
88
101
105
Net profit (m)
85
104
105
110
112
112
113
111
108
104
76
126
96
229
140
272
262
Income tax rate
34.0%
32.7%
32.3%
29.8%
31.9%
30.7%
29.9%
31.3%
30.1%
29.2%
32.0%
(0.2)%
14.2%
17.1%
5.8%
12.7%
18.1%
Net profit margin
38.1%
40.2%
39.9%
40.8%
38.7%
35.7%
36.2%
31.0%
23.8%
20.9%
13.5%
19.6%
13.5%
31.0%
15.1%
24.6%
23.5%
Working capital (m)
196
238
240
184
212
311
377
443
209
200
213
319
311
414
358
430
437
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
7
73
92
344
339
493
344
396
302
278
Equity (m)
438
487
456
502
586
674
738
795
847
879
950
1,079
1,166
1,381
1,563
1,702
1,827
ROIC
19.4%
21.3%
23.1%
21.9%
18.7%
16.4%
15.1%
13.3%
10.6%
9.8%
5.7%
9.0%
6.4%
12.8%
7.3%
13.3%
12.0%
Return on capital
28.3%
30.3%
32.9%
30.2%
26.7%
22.5%
20.6%
18.7%
14.6%
13.2%
7.7%
8.5%
7.1%
14.6%
7.2%
14.0%
13.8%
Return on equity
19.4%
21.3%
23.1%
21.9%
19.2%
16.7%
15.3%
14.0%
12.7%
11.9%
8.0%
11.7%
8.2%
16.6%
9.0%
16.0%
14.3%
Plowback ratio
100.0%
100.0%
73.2%
65.0%
64.7%
63.5%
61.4%
59.1%
56.3%
54.4%
37.8%
62.0%
49.7%
78.7%
64.7%
81.6%
80.8%
Div.&Repurch./FCF
(1.8)%
57.7%
114.1%
47.6%
33.9%
54.3%
45.4%
36.9%
39.4%
37.5%
36.9%
32.1%
40.8%
64.5%
30.1%
75.3%
91.6%
Capital Structure
7 Feb · 2023 | Q2
All numbers in millions
Total liabilities
$ 536
Total assets
$ 2,363
Long-term debt
$ 278
Cash and equiv.
$ 165
Goodwill
$ - -
Retained earnings
$ - -
Common stock
157
Enterprise Value
$ 12,461
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
271
232
247
Receivables
123
145
195
Inventory
103
117
141
Other
24
69
49
Current assets
521
511
606
Acc. Payable
23
29
34
Debt due
22
24
24
Other
62
99
118
Current liabilities
107
152
176
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
18.75%
14.82%
15.36%
Cash flow
(8.93)%
23.61%
15.22%
Earnings
93.75%
42.45%
22.34%
Dividends
1.13%
1.13%
1.62%
Book value
8.88%
12.14%
9.81%
Insider Trading
Type
Shares
Date
Kummeth Charles R.
Exempt
407,364
01/04/23
Kummeth Charles R.
InKind
255,837
01/04/23
Kummeth Charles R.
Exempt
407,364
01/04/23
Furlow Brenda S.
Exempt
7,450
12/08/22
Furlow Brenda S.
Sale
7,450
12/08/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
204
224
244
259
931
2022
258
269
290
288
1,106
2023
270
272
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.22
0.30
0.30
0.10
0.91
2022
0.44
0.51
0.39
0.39
1.73
2023
0.57
0.32
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.08
0.08
0.08
0.08
0.32
2022
0.08
0.08
0.08
0.08
0.32
2023
0.08
0.08
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Charles R. Kummeth
Full-time employees:
3,000
City:
Minneapolis
Address:
614 McKinley Place N.E.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.